Table 3.
Reference | Histology | Method | Sensitivity | Type of comparison | Suggested clinical application |
---|---|---|---|---|---|
Muller et al. 2014 | 141 GBM | Density gradient centrifugation | 20.6% | with 23 healthy controls | Diagnosis Prognosis |
Sullivan et al. 2014 | 33 GBM | CTC- i-CHIP technology | 39.3% | none | Monitoring |
Macarthur et al. 2014 | 11 GBM | Density gradient centrifugation | 72% baseline 8% after radiotherapy |
with 30 healthy controls | Monitoring |
Gao et al. 2016 | 31 (grade II, III, and IV) |
Matrix isolation | 77% | no with 10 healthy controls | Diagnosis Monitoring |
Krol et al. 2018 | 13 GBM | Microfluidic technology | 53.8% | with 3 healthy controls | Diagnosis Monitoring |
GBM: glioblastoma.